Methenamine
Hiprex, Methenamine Hippurate, Urex (methenamine) is a small molecule pharmaceutical. Methenamine was first approved as Urex on 1982-01-01. It is used to treat bacteriuria, cystitis, escherichia coli infections, and staphylococcal infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| all-in-one uti emergency kit | unapproved drug other | 2024-12-17 |
| azo urinary tract defense | unapproved drug other | 2020-12-12 |
| cvs antibacterial plus urinary pain relief | unapproved drug other | 2024-12-18 |
| cvs dual action pain relief | unapproved drug other | 2024-12-18 |
| cystex | C200263 | 2024-12-20 |
| good neighbor antibacterial plus urinary pain relief | unapproved drug other | 2024-12-18 |
| hiprex | New Drug Application | 2025-01-16 |
| hyophen | unapproved drug other | 2017-01-05 |
| mb caps | unapproved drug other | 2025-02-25 |
| meijer antibacterial plus urinary pain relief | unapproved drug other | 2024-12-18 |
Show 27 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methenamine |
| INN | methenamine |
| Description | Hexamethylenetetramine is a polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms. It has a role as an antibacterial drug. It is a polycyclic cage, a polyazaalkane and a tetramine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C1N2CN3CN1CN(C2)C3 |
Identifiers
| PDB | — |
| CAS-ID | 100-97-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201270 |
| ChEBI ID | 6824 |
| PubChem CID | 4101 |
| DrugBank | DB06799 |
| UNII ID | J50OIX95QV (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Methenamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 23,885 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
421 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use